Skip to main content
SpringerLink
Log in

Konservative Behandlungsmethoden anogenitaler HPV-Infektionen

Conservative treatment of anogenital HPV infections

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Trotz einiger hoffnungsvoller therapeutischer Entwicklungen, wie z. B. die Lokaltherapie mit einer Salbe aus Derivaten des grünen Tees, bleibt die Therapie der anogenitalen Warzen ein Problem. Sowohl ärztliche Behandlungen als auch die Selbstbehandlung durch die Patienten sind nicht völlig zufriedenstellend. Die aktuellen Therapieformen mit hohen Rezidivquoten zusammen mit der zunehmenden Inzidenz und Krankheitslast sind Indikatoren dafür, dass die quadrivalente prophylaktische VLP („virus like particle“)-HPV-6-, -11-, -16-, -18-Vakzine zur Kontrolle HPV-assoziierter Neoplasien wie anogenitale Warzen vermehrt eingesetzt werden sollte.

Abstract

Despite some recent hopeful therapeutic developments such as topical green tea derivatives, the therapy of anogenital warts remains a medical problem. Both physician- and self-administered therapeutic approaches are not fully satisfactory. The high recurrence rates associated with the current therapy of anogenital warts together with their increasing incidence and burden of disease further support the use of the prophylactic quadrivalent VLP HPV 6,11,16,18 vaccine for control of HPV-associated neoplasias in women and men.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Abdullah AN, Walzman M, Wade A (1993) Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 20(6):344–345

    Article  CAS  PubMed  Google Scholar 

  2. CDC (1998) Human papillomavirus Infection. Guidelines for treatment of sexually transmitted diseases. MMWR 47:88–98

    Google Scholar 

  3. Clinical Effectiveness Group (Association of Genitourinary Medicine and Medical Society for the study of venereal Disease) (1999) National guideline for the management of anogenital warts. Sex Transm Infect 75(Suppl 1):S71–S75

    Google Scholar 

  4. Chuang TY, Perry HO, Kurland LT, Ilstrup DM (1984) Condyloma acuminatum in Rochester, Minn 1950–1978 (1984) I. Epidermiology and clinical features. Arch Dermatol 120:469–475

    Article  CAS  PubMed  Google Scholar 

  5. Dediol I, Buljan M, Vurnek A et al (2009) Psychological burden of anogenital warts. J Eur Acad Dermatol Venereol 23(9):1035–1038

    Article  CAS  PubMed  Google Scholar 

  6. Dachów-Siwiéc E (1990) Treatment of cryosurgery in the premalignant and benign lesions of the skin. Clin Dermatol 8(1):69–79

    Article  PubMed  Google Scholar 

  7. Edwards L, Ferenczy A, Eron L et al (1998) Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 134(1):25–30

    Article  CAS  PubMed  Google Scholar 

  8. Fairley CK, Hocking JS, Gurrin LC et al (2009) Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85(7):499–502

    Article  CAS  PubMed  Google Scholar 

  9. Fenton KA, Lowndes CM (2004) Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Transm Infect 80(4):255–263

    Article  CAS  PubMed  Google Scholar 

  10. Forcier M, Musacchio N (2010) An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther 23(5):458–476

    Article  PubMed  Google Scholar 

  11. Fox PA, Tung MY (2005) Human papillomavirus: burden of illness and treatment cost considerations. Am J Clin Dermatol 6:365–381

    Article  PubMed  Google Scholar 

  12. Garland SM, Sellors JW, Wikstrom A et al (2001) Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts – results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 12(11):722–729

    Article  CAS  PubMed  Google Scholar 

  13. Gollnick H, Barasso R, Jappe U et al (2001) Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 12(1):22–28

    Article  CAS  PubMed  Google Scholar 

  14. Gross G (1995) Treatment of human papillomavirus infection. In: Mindel A (Hrsg) Genital warts. Human papillomavirus infection. Edward Arnold, London Boston Melbourne Auckland, S 198–236

  15. Gross G (2001) Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions. Hautarzt 52(1):6–17

    Article  CAS  PubMed  Google Scholar 

  16. Gross G, Meyer KG, Pres H et al (2007) A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venereol 21(10):1404–1412

    Article  CAS  PubMed  Google Scholar 

  17. Gross G (2008) HPV-Impfungen wichtig für Dermatologen. Hautarzt 11:929–932

    Article  Google Scholar 

  18. Gross G (2008) Polyphenon® E. Eine neue topische Therapie für Condylomata acuminata. Hautarzt 59:31–35

    Article  CAS  PubMed  Google Scholar 

  19. Gross G, Ikenberg H, Petry KU et al (2008) Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder des Genitale und der Harnröhre, Leitlinie der Deutschen STD-Gesellschaft. J Dtsch Dermatol Ges 2:153–163

    Google Scholar 

  20. Gross G (2009) Differenzialdiagnostik anogenitaler Condylomata acuminata. Indikation für die histopathologische Untersuchung. Hautarzt 6:465–471

    Article  Google Scholar 

  21. Hogewoning CJ, Bleeker MC, Brule AJ van den et al (2003) Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 107(5):811–816

    Article  CAS  PubMed  Google Scholar 

  22. Hemmi H, Kaisho T, Takeuchi O et al (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3(2):196–200

    Article  CAS  PubMed  Google Scholar 

  23. Hillemanns P, Breugelmans JG, Gieseking F et al (2008) Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis 8:76

    Article  PubMed  Google Scholar 

  24. Insinga RP, Dasbach EJ, Myers ER (2003) The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36(11):1397–1403

    Article  PubMed  Google Scholar 

  25. Kjaer SK, Tran TN, Sparen P et al (2007) The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 196(10):1447–1454

    Article  PubMed  Google Scholar 

  26. Koshiol JE, Laurent SA, Pimenta JM (2004) Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 31(12):748–752

    Article  PubMed  Google Scholar 

  27. Koutsky LA, Galloway DA, Holmes KK (1988) Epidemiology of genital papillomavirus infection. Epidemiol Rev 10:122–163

    CAS  PubMed  Google Scholar 

  28. Lacey CJ (2005) Therapy for genital human papillomavirus-related disease. J Clin Virol 32(Suppl 1):S82–S90

    Article  CAS  PubMed  Google Scholar 

  29. Maw R (2004) Critical appraisal of commonly used treatment for genital warts. Int J STD AIDS 15(6):357–364 (Review)

    Article  PubMed  Google Scholar 

  30. Miller RL, Gerster JF, Owens ML et al (1999) Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 21(1):1–14

    Article  CAS  PubMed  Google Scholar 

  31. Perry CM, Lamb HM (1999) Topical imiquimod: a review of its use in genital warts. Drugs 58(2):375–390

    Article  CAS  PubMed  Google Scholar 

  32. Petzoldt D, Gross G (Hrsg) (2001) Diagnostik und Therapie sexuell übertragbarer Krankheiten. Leitlinien 2001 der Deutschen STD-Gesellschaft. Springer, Berlin Heidelberg

  33. Pirotta M, Ung L, Stein A et al (2009) The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 85(7):508–513

    Article  CAS  PubMed  Google Scholar 

  34. Schürmann D, Bergmann F, Temmesfeld-Wollbrück B et al (2000) Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 14(8):1075–1076

    Article  PubMed  Google Scholar 

  35. Silverberg MJ, Ahdieh L, Munoz A et al (2002) The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 29:427–435

    Article  PubMed  Google Scholar 

  36. Silverberg MJ, Thorsen P, Lindeberg H et al (2003) Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 101(4):645–652

    Article  PubMed  Google Scholar 

  37. Simms I, Fairley CK (1997) Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med 73(5):365–367

    CAS  PubMed  Google Scholar 

  38. Stockfleth E, Beti H, Orasan R et al (2008) Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol 158(6):1329–1338

    Article  CAS  PubMed  Google Scholar 

  39. Tatti S, Swinehart JM, Thielert C et al (2008) Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol 111(6):1371–1379

    Article  PubMed  Google Scholar 

  40. Tyring S, Edwards L, Cherry LK et al (1998) Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 134(1):33–38

    Article  CAS  PubMed  Google Scholar 

  41. Krogh G von, Lacey CJ, Gross G et al (2000) European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 76(3):162–168

    Article  Google Scholar 

  42. Wiley DJ, Douglas J, Beutner K et al (2002) External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 35(Suppl 2):S210–S224

    Article  CAS  PubMed  Google Scholar 

  43. Woodhall S, Ramsey T, Cai C et al (2008) Estimation of the impact of genital warts in health-related quality of life. Sex Transm Infect 84(3):161–166

    Article  CAS  PubMed  Google Scholar 

  44. zur Hausen H (1977) Human papillomaviruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol 78:1–30

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: G.G. hat Honorare für Vorträge über die Entwicklung und Anwendung der HPV-Vakzine von Sanofi Pasteur MSD und für die Therapie genitoanaler Warzen mit Polyphenon E von Abbott erhalten.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Venerologie, Universität Rostock, Strempelstr. 13, 18057, Rostock, Deutschland

    G. Gross

Authors
  1. G. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Gross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gross, G. Konservative Behandlungsmethoden anogenitaler HPV-Infektionen. Hautarzt 62, 34–39 (2011). https://doi.org/10.1007/s00105-010-2036-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-2036-2

Schlüsselwörter

Keywords

Search

Navigation